PreView Medical – Transforming prostate cancer care with AI-powered spectroscopy

cancer care

with

Transforming prostate

AI-powered spectroscopy

LEARN MORE

↓

cancer care

with

Transforming prostate

AI-powered

LEARN MORE

spectroscopy

↓

Prostate cancer is the 2nd most common cancer in men.

1 IN 8 MEN WILL GET IT IN THEIR LIFETIME…

…but prostate cancer diagnosis and treatment have major limitations.

SOLUTIONS

PreView Medical has developed two systems to improve detection and precisely locate and treat prostate cancer:

The ClariCore^® Biopsy System

LEARN MORE →

The ClariCore^® Mapping System

LEARN MORE →

PROSTATE BIOPSY

The ClariCore^® Biopsy System uses AI-powered Spectroscopy to classify tissue as benign or suspicious in real time during a prostate biopsy.

In a standard biopsy, tissue samples are taken randomly from the prostate and evaluated by pathology. This approach can miss almost half of all cancers.
With ClariCore^®, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.
The returned light is instantaneously analyzed by a spectrometer and an AI algorithm, classifying the tissue as benign or suspicious. This has the potential to find more cancers.

In a standard biopsy, tissue samples are taken randomly from the prostate and evaluated by pathology. This approach can miss almost half of all cancers.

With ClariCore^®, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.

The returned light is instantaneously analyzed by a spectrometer and an AI algorithm, classifying the tissue as benign or suspicious. This has the potential to find more cancers.

In a 144 patient multi-center study, ClariCore^® was shown to have very high accuracy in classifying tissue:

86 %

SENSITIVITY

88 %

SPECIFICITY

97 %

NEGATIVE PREDICTIVE VALUE

FOCAL THERAPY

The ClariCore^® Mapping System is designed to enable the delivery of energy to the exact location of cancer.

Patients with clinically significant prostate cancer often receive a radical prostatectomy, in which the entire prostate is removed. Unfortunately, this procedure can have a high rate of complications, including erectile dysfunction and incontinence.
PreView’s ClariCore^® Mapping System is designed to guide focal therapy procedures that allow treatment without removing the prostate. The system uses spectroscopy to create a precise 3D map of the cancer.
Once ClariCore^® creates the 3D map, the physician can deliver energy to the exact location of the tumor. This has the potential to treat the cancer while sparing healthy prostate tissue.

Patients with clinically significant prostate cancer often receive a radical prostatectomy, in which the entire prostate is removed. Unfortunately, this procedure can have a high rate of complications, including incontinence and erectile dysfunction.

PreView’s ClariCore Mapping System is designed to guide focal therapy procedures that allow treatment without removing the prostate. The system uses spectroscopy to create a precise 3D map of the cancer.

Once ClariCore^® creates the 3D map, the physician can deliver energy to the exact location of the tumor. This has the potential to treat the cancer while sparing healthy prostate tissue.

Prostate cancer is the 2nd most common cancer in men.

1 IN 8 MEN WILL GET IT IN THEIR LIFETIME…

…but prostate cancer diagnosis and treatment have major limitations.

PreView Medical has developed two systems to improve detection and precisely locate and treat prostate cancer:

The ClariCore^® Biopsy System

The ClariCore^® Mapping System

The ClariCore^® Biopsy System uses AI-powered Spectroscopy to classify tissue as benign or suspicious in real time during a prostate biopsy.

In a standard biopsy, tissue samples are taken randomly from the prostate and evaluated by pathology. This approach can miss almost half of all cancers.

With ClariCore^®, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.

The returned light is instantaneously analyzed by a spectrometer and an AI algorithm, classifying the tissue as benign or suspicious. This has the potential to find more cancers.

In a 144 patient multi-center study, ClariCore^® was shown to have very high accuracy in classifying tissue:

SENSITIVITY

SPECIFICITY

NEGATIVE PREDICTIVE VALUE

The ClariCore^® Mapping System is designed to enable the delivery of energy to the exact location of cancer.

Patients with clinically significant prostate cancer often receive a radical prostatectomy, in which the entire prostate is removed. Unfortunately, this procedure can have a high rate of complications, including incontinence and erectile dysfunction.

PreView’s ClariCore Mapping System is designed to guide focal therapy procedures that allow treatment without removing the prostate. The system uses spectroscopy to create a precise 3D map of the cancer.

Once ClariCore^® creates the 3D map, the physician can deliver energy to the exact location of the tumor. This has the potential to treat the cancer while sparing healthy prostate tissue.

Contact us for more information

[email protected] 866-519-VIEW(8439)

Prostate cancer is the 2nd most common cancer in men.

1 IN 8 MEN WILL GET IT IN THEIR LIFETIME…

…but prostate cancer diagnosis and treatment have major limitations.

PreView Medical has developed two systems to improve detection and precisely locate and treat prostate cancer:

The ClariCore® Biopsy System

The ClariCore® Mapping System

The ClariCore® Biopsy System uses AI-powered Spectroscopy to classify tissue as benign or suspicious in real time during a prostate biopsy.

In a standard biopsy, tissue samples are taken randomly from the prostate and evaluated by pathology. This approach can miss almost half of all cancers.

With ClariCore®, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.

The returned light is instantaneously analyzed by a spectrometer and an AI algorithm, classifying the tissue as benign or suspicious. This has the potential to find more cancers.

In a 144 patient multi-center study, ClariCore® was shown to have very high accuracy in classifying tissue:

SENSITIVITY

SPECIFICITY

NEGATIVE PREDICTIVE VALUE

The ClariCore® Mapping System is designed to enable the delivery of energy to the exact location of cancer.

Patients with clinically significant prostate cancer often receive a radical prostatectomy, in which the entire prostate is removed. Unfortunately, this procedure can have a high rate of complications, including incontinence and erectile dysfunction.

PreView’s ClariCore Mapping System is designed to guide focal therapy procedures that allow treatment without removing the prostate. The system uses spectroscopy to create a precise 3D map of the cancer.

Once ClariCore® creates the 3D map, the physician can deliver energy to the exact location of the tumor. This has the potential to treat the cancer while sparing healthy prostate tissue.

Contact us for more information

[email protected] 866-519-VIEW(8439)

The ClariCore^® Biopsy System

The ClariCore^® Mapping System

The ClariCore^® Biopsy System uses AI-powered Spectroscopy to classify tissue as benign or suspicious in real time during a prostate biopsy.

With ClariCore^®, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.

In a 144 patient multi-center study, ClariCore^® was shown to have very high accuracy in classifying tissue:

The ClariCore^® Mapping System is designed to enable the delivery of energy to the exact location of cancer.

Once ClariCore^® creates the 3D map, the physician can deliver energy to the exact location of the tumor. This has the potential to treat the cancer while sparing healthy prostate tissue.